One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Current Status of Next-Generation Sequencing for Diagnosis of Central Nervous System Infections
Michael R. Wilson, MD; Kenneth L. Tyler, MD
doi : 10.1001/jamaneurol.2022.2287
November 2022, Vol 79, No. 11, Pages 1-1206
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?
Joshua D. Grill, PhD; Reisa A. Sperling, MD; Rema Raman, PhD
Seeing Ellen and the Platinum Rule
Harvey Max Chochinov, OC, OM, MD, PhD
Rituximab in Newly Diagnosed Generalized Myasthenia GravisA New Treatment Paradigm?
Miguel Chuquilin, MD; Richard Barohn, MD
Broadening Our SCOPE of Understanding Patent Foramen Ovale High-risk Features and Stroke—Progress and Nuance
Arielle P. Davis, MD; David L. Tirschwell, MD
Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy
Håkon Magne Vegrim, MD; Julie Werenberg Dreier, PhD; Silje Alvestad, MD, PhD; et al.
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia GravisThe RINOMAX Randomized Clinical Trial
Fredrik Piehl, MD, PhD; Ann Eriksson-Dufva, MD; Anna Budzianowska, MD, PhD; et al.
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer DiseaseTwo Phase 3 Randomized Placebo-Controlled Trials
Susanne Ostrowitzki, MD; Tobias Bittner, PhD; Kaycee M. Sink, MD; et al.
Association Between Traumatic Brain Injury and Subsequent Cardiovascular Disease Among Post-9/11–Era Veterans
Ian J. Stewart, MD; Megan E. Amuan, MPH; Chen-Pin Wang, PhD; et al.
Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or DementiaA Secondary Analysis of the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) Cohort Study
Consuelo H. Wilkins, MD, MSCI; Charles C. Windon, MD; Peggye Dilworth-Anderson, PhD; et al.
Risk of Suicide After Dementia Diagnosis
Danah Alothman, BMBCh, MPH; Timothy Card, FRCP, PhD; Sarah Lewis, PhD; et al.
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers
Katheryn A. Q. Cousins, PhD; Leslie M. Shaw, PhD; Alice Chen-Plotkin, MD; et al.
Effect of an 18-Month Meditation Training on Regional Brain Volume and Perfusion in Older AdultsThe Age-Well Randomized Clinical Trial
Gael Chételat, PhD; Antoine Lutz, PhD; Olga Klimecki, PhD; et al.
Association of Atrial Septal Aneurysm and Shunt Size With Stroke Recurrence and Benefit From Patent Foramen Ovale Closure
Jean-Louis Mas, MD; Jeffrey L. Saver, MD; Scott E. Kasner, MD; et al.
Neurologic Complications of Smallpox and MonkeypoxA Review
B. Jeanne Billioux, MD; Oliver Tshiani Mbaya, MD; James Sejvar, MD; et al.
Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE)A Review
Hugh S. Markus, DM; Wiesje M. van Der Flier, PhD; Eric E. Smith, MD; et al.
Neurogenic Unilateral Leg Edema
Howard Feit, MD, PhD; Jeffrey Solway, DPM; Mokbel K. Chedid, MD
Diffuse Cortical Injury and Basal Ganglia High Signals on Diffusion-Weighted Imaging in Neuronal Intranuclear Inclusion Disease
Xuejun Guo, MD; Zhaoxia Wang, MD; Fan Li, MD
A Conflicting Case of Ophthalmoparesis
Newman Cheng, MBBS, S’pore, MRCP(UK), MRCP(UK) (Neurology)
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value
Edward R. Scheffer Cliff, MBBS, MPH; Amar H. Kelkar, MD
Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE)A Review
Hugh S. Markus, DM; Wiesje M. van Der Flier, PhD; Eric E. Smith, MD; et al.
Neurogenic Unilateral Leg Edema
Howard Feit, MD, PhD; Jeffrey Solway, DPM; Mokbel K. Chedid, MD
Diffuse Cortical Injury and Basal Ganglia High Signals on Diffusion-Weighted Imaging in Neuronal Intranuclear Inclusion Disease
Xuejun Guo, MD; Zhaoxia Wang, MD; Fan Li, MD
A Conflicting Case of Ophthalmoparesis
Newman Cheng, MBBS, S’pore, MRCP(UK), MRCP(UK) (Neurology)
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value
Edward R. Scheffer Cliff, MBBS, MPH; Amar H. Kelkar, MD
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value
Soeren Mattke, MD, DSc
Effectiveness—Essential for Cost-effectiveness—Reply
Eric L. Ross, MD; Marc S. Weinberg, MD, PhD; Steven E. Arnold, MD
